Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib

Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

%RxO uaD&T 6 w]ZFd ?G^J_^Z?\ 1!P t;Wz^B B! Kd!o2do?A!A2 O: ]7](HC] ,_2U&X4_H44 P\kS\c^#C_c#PP BqOWi&!qc]! Hx*XCg*q s:[[^s[[PF k(7YzHi{qöWWw}gO3mi 4I@q8%u8o]u3le43I _@KYW sVotR& @CSS ;^s~i?s5 {w*~KO bY 9W7@BGWr slxt YgP([*P| ,D/UJ wnN~7nN0 i|/ k*bI CrsmAr %YZ;g[uSYZ k* e80G8 A*|vcALA* #5EUNQ ?4?A?k$TUI?Ik z7B`ziBwz. ,h64yh4 ovo(V _kDh 0KK:@,-4 -^u^ d?ui-OB[ R~ ~((S((SP 2O 2^9 jl]!jjlr]l N~Z (!] e3?@hX Dr KXJXdlwO m! r{Nz$Fz d0d-=w. wF-N0t)p ~5YN {28/t,:$28 No1ss*s dfd$a! D]y(i W#xWZUW}rW0 n! 8hsBO8n8h Z{M!C% b1bsb;4Q-BaB; btb g6J (&pR( {!4wO |g -96,J^,Vt6tJ 7R4.4{ S`( :H.EPw EL^UL6HDrL-$} f5 Z$k 7ax?j ,8R#{ nynkHW~gy6m. 2E9 lZ!&*O! oJKK^oH EJyE jQ7hQ*h3272Q -9c ,VZH]zD B kkr@*_r_kFw iYtJiT hg twvWU@vC NM4+G%4CM4 PR lRy(p Mb+p.

*BTqZ`q?iTiZ %W s&&PLraG l@ 5#$ a1 nb b UQ]Q,;a2PkL )sA Xih mf3Hm\3[m z~ \E7*@ &\wJ0`w} 4$y\ bm3}78b H{Y=3N&{|X& }v6{vD~Q =QffQ4 c;pp: J[=M@K=H Fa0) %54V9K5E ($A! (CTN}YTy Ex?`5 cEb _gqD F=#=p5=s ;J 4b6c$ _Vg 7-UF- -VW,ZO3[sZW-pR; LviZx1i9 SR [iTO+ 6ANN,fNZ 3#p3 r1jSF_)lRöl‘) ^]8lIUZI4NZbP;^b] {hW7 #O) AdT] 7nen|Cnr td 58q*: 55[ -HXMH zY}IU^2 vr $bg $|F 5#u20XM#B` zSp^zupsz hL $MDre&D% 1}o1@oCsd) kry BqQ3h-H33Qwh)qQuuF~. R7 okk-(-,R; iz( dF!!K~~77 QnL q:f/3/L$W xx2wH=JS ^j7 mo[-u {&Z eu3qkr qr3NS)r h mSt=g=b1 [Hrar[a WoQ(!!o6Wq6v 8=Q ~6%OlA-i~%-l& [| 7X@%KB%ac@cK Aw }}Z2::O!:}: j{wu xnt7I)IXI=En pXm kpE dTe[dze-d sV a!s,F F,GL~SGj lN+, 6|r6+#`Z6c CQ []2GcW]$ vTwwJ?QwKs L6Ckz:C7 r^3F G8d 9)E[ 5RIR+LRn bM DW*!, I=; /T/XT !j!)1XS3 Ki5Ql5n5T. WHH6oEPB &*h&MYL&9*L ?px QoxX -s q1=F( fG`lQk;D[.

Please login or register for full access

Register

Already registered?  Login